// App-Quantinova.ai

: Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study

Researchers

Presenter

  • Meletios A. Dimopoulos

Principal Investigators

  • Mario Boccadoro

  • Sosana Delimpasi

  • Meral Beksac

  • Eirini Katodritou

  • Philippe Moreau

  • Luca Baldini

  • Argiris Symeonidis

  • Jelena Bila

  • Albert Oriol

  • Maria-Victoria Mateos

  • Hermann Einsele

  • Ioannis Orfanidis

  • Tobias Kampfenkel

  • Weiping Liu

  • Michele Kosh

  • Namphuong Tran

  • Robin Carson

  • Pieter Sonneveld

Medical Centers

  • Würzburg University Medical Centre, Würzburg, Germany

  • Erasmus MC Cancer Institute, Rotterdam, Netherlands

  • Institut Català d'Oncologia and Institut Josep Carreras. Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

  • Janssen Research & Development, Neuss, Germany

  • Department of Hematology, Lymphoma and BMT Unit, Evangelismos Hospital, Athens, Greece

  • University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, ATHENS, Greece

  • National and Kapodistrian University of Athens, Athens, Greece

  • Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

  • UO Ematologia, Fondazione IRCCS Cà Granda, OM Policlinico, Università degli Studi, Milan, Italy

  • Health Data Specialists S.A., Dublin, Ireland

  • University Clinical Center of Serbia, Belgrade, Serbia

  • Hematology Division, Department of Internal Medicine, University of Patras, Patras, Greece

  • Department of Haematology, Theagenion Anticancer General Hospital, Thessaloniki, Greece

  • Ankara University, Ankara, Turkey

  • Hematology Department, University Hospital Hôtel-Dieu, Nantes, France

Locations

  • Germany

  • Greece

  • Italy

  • United States

  • Netherlands

  • China

  • Spain

  • Ireland

  • Turkey

  • Serbia

  • France

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Hyaluronidase

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • daratumumab Intravenous

  • Enhanze

  • rHuPH20

Outcome

  • N/A

Study Design

  • Randomized

  • Multinational

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved